Skip to main content
. Author manuscript; available in PMC: 2021 May 27.
Published in final edited form as: Toxicol Appl Pharmacol. 2013 Oct 4;273(3):516–523. doi: 10.1016/j.taap.2013.09.022

Table 3.

Multi-log regression (OR and 95% CI) in children and adolescent participants in NHANES 1999–2006, NHANES 1999–2002 and NHANES 2003–2006.a

Participants, % (SE)b Normal Overweight Obese

NHANES 1999–2006; n = 10693 6923 1716 2054
 BLL quartile 1 (≤0.70 μg/dL) 1 (reference) 1 (reference) 1 (reference)
 BLL quartile 2 (0.71–1.09 μg/dL) 1 (reference) 0.93 (0.77–1.13) 0.82 (0.67–1.00)
 BLL quartile 3 (1.10–1.60 μg/dL) 1 (reference) 0.87 (0.67–1.11) 0.70 (0.54–0.90)
 BLL quartile 4 (≥1.61 μg/dL) 1 (reference) 0.67 (0.52–0.88) 0.42 (0.30–0.59)
NHANES 1999–2002; n=4920 3245 764 911
 BLL quartile 1 (≤0.70 μg/dL) 20.3 (1.02) 1 (reference) 1 (reference) 1 (reference)
 BLL quartile 2 (0.71–1.09 μg/dL) 22.0 (0.96) 1 (reference) 1.11 (0.75–1.62) 0.92 (0.67–1.28)
 BLL quartile 3 (1.10–1.60 μg/dL) 28.7 (0.77) 1 (reference) 0.96 (0.62–1.49) 0.73 (0.49–1.10)
 BLL quartile 4 (≥1.61 μg/dL) 29.0 (1.41) 1 (reference) 0.63 (0.41–0.99) 0.49 (0.27–0.89)
NHANES 2003–2006; n = 5773 3678 952 1143
 BLL quartile 1 (≤0.70 μg/dL) 29.4 (1.55) 1 (reference) 1 (reference) 1 (reference)
 BLL quartile 2 (0.71–1.09 μg/dL) 27.1 (1.12) 1 (reference) 0.85 (0.69–1.05) 0.76 (0.58–0.99)
 BLL quartile 3 (1.10–1.60 μg/dL) 22.6 (0.93) 1 (reference) 0.82 (0.60–1.14) 0.70 (0.50–0.99)
 BLL quartile 4 (≥1.61 μg/dL) 20.9 (1.3) 1 (reference) 0.78 (0.55–1.10) 0.38 (0.26–0.55)
a

Adjusted for age, gender, race/ethnicity, hematocrit, calorie intake, TV and video game use, serum cotinine, and poverty income ratio.

b

Percentages are sample-weighted for applicability to the U.S. population.